# Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke

> **NCT02251197** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 97 (actual)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** BIII 890 CL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02251197
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** 2002-10
- **Final completion:** —
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2014-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02251197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02251197, "Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02251197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*